Company achieved second positive Phase III study for lead candidate DT120 ODT with statistically significant efficacy results, rapid onset of action, acceptable safety profile, and clear regulatory pathway with FDA pre-NDA meeting scheduled. Stock has gained 200.6% year-to-date. Program expanding into additional indications (MDD, PTSD) strengthens pipeline prospects.
Articles that tag DFTX but are mainly about other companies.
Stock rose ~25% in the last month. MM120 candidate for generalized anxiety disorder has large addressable market. Company has $258 million in cash providing runway. 14 Buy ratings with only 1 Sell and ~70% upside potential. Most optimistic analyst sentiment of the three companies.
Stock rose 4% following the announcement. Company has breakthrough therapy designation and is evaluating psychedelic drugs for anxiety disorder and major depressive disorder, positioning it to benefit from expedited FDA reviews.
Rebranded to signal transition to late-stage psychiatry company, lead candidate DT120 has FDA Breakthrough Therapy Designation, three Phase 3 readouts expected in 2026, and fourth Phase 3 planned for mid-year initiation targeting large patient populations.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
